8 years of historical data (2018–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nurix Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.6B | $1.5B | $1.5B | $338M | $602M | $1.2B | $668M | — | — |
| Enterprise Value | $1.4B | $1.3B | $1.4B | $314M | $550M | $1.2B | $549M | — | — |
| P/E Ratio → | -5.24 | — | — | — | — | — | — | — | — |
| P/S Ratio | 19.36 | 18.25 | 27.21 | 4.39 | 15.59 | 41.55 | 37.49 | — | — |
| P/B Ratio | 2.57 | 2.84 | 2.82 | 1.69 | 1.98 | 3.61 | 2.30 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.97 | 25.71 | 4.08 | 14.23 | 39.29 | 30.79 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Nurix Therapeutics, Inc. earns an operating margin of -340.2%. Operating margins have compressed from -201.4% to -340.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -49.6% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 77.5% | -306.3% | -145.7% | -377.6% | -291.4% | -273.1% | -44.7% | -8.2% |
| Operating Margin | -340.2% | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% | -364.7% | -71.5% | -26.0% |
| Net Profit Margin | -314.9% | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% | -69.7% | -25.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.6% | -49.6% | -53.2% | -57.1% | -55.8% | -37.1% | -37.2% | — | — |
| ROA | -39.0% | -39.0% | -37.8% | -37.3% | -40.4% | -26.8% | -19.6% | -48.5% | -20.8% |
| ROIC | -54.0% | -54.0% | -51.4% | -54.4% | -52.4% | -39.7% | -124.4% | — | — |
| ROCE | -48.6% | -48.6% | -50.6% | -50.4% | -48.6% | -30.9% | -34.2% | -109.9% | -77.5% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $247M exceeds total debt of $56M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.05 | 0.15 | 0.04 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.16 | -0.12 | -0.17 | -0.20 | -0.41 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($247M) exceeds total debt ($56M)
Short-term solvency ratios and asset-utilisation metrics
Nurix Therapeutics, Inc.'s current ratio of 7.02x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.40x to 7.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.02 | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 | 6.70 | 2.44 | 1.24 |
| Quick Ratio | 7.02 | 7.02 | 6.46 | 3.40 | 4.52 | 4.70 | 6.70 | 2.44 | 1.24 |
| Cash Ratio | 6.86 | 6.86 | 6.36 | 3.31 | 4.38 | 4.46 | 6.31 | 2.34 | 1.19 |
| Asset Turnover | — | 0.12 | 0.08 | 0.22 | 0.09 | 0.06 | 0.04 | 0.71 | 0.82 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 10.04 | 3.79 | 10.39 | 76.12 | 232.40 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nurix Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $87M | $67M | $54M | $49M | $43M | $16M | $39M | $16M |
Compare NRIX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| NRIXYou | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how NRIX stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonNurix Therapeutics, Inc.'s current P/E ratio is -5.2x. This places it at the 50th percentile of its historical range.
Nurix Therapeutics, Inc.'s return on equity (ROE) is -49.6%. The historical average is -48.3%.
Based on historical data, Nurix Therapeutics, Inc. is trading at a P/E of -5.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Nurix Therapeutics, Inc. has 77.5% gross margin and -340.2% operating margin.